课题基金 / 基金详情

Mice Humanized with Hepatocytes and iPS Cells from Patients with Metabolic Diseas

Mice Humanized with Hepatocytes and iPS Cells from Patients with Metabolic Diseas
用代谢疾病患者的肝细胞和 iPS 细胞人源化小鼠
批准号:
7812582
负责人:
Stephen C Strom
金额:
$47.79万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-30 至 2011-07-31

项目摘要

项目成果

Stephen C Strom的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):特殊挑战主题14-DK-101,“诱导多能干细胞-细胞和人源化小鼠”身体细胞,如来自疾病患者的成纤维细胞,可通过诱导多能干细胞(IPSC)技术,创建细胞系、组织,甚至器官系统。这样的模型可以用来阐明疾病的潜在病理,或者筛选可以用于治疗的药物。将这种方法与能够接受多个人类组织而不产生排斥反应的小鼠品系相结合,可以提供微环境环境,在整个生物体的背景下支持组织的生理功能,使人们能够更好地了解疾病的发病机制,并为候选药物的临床前测试提供平台。“肝脏发挥着对维持机体至关重要的3000多项功能,从白蛋白、凝血因子和抗蛋白酶等蛋白质的产生和分泌,到药物或毒素等外源化合物的代谢和排泄,以及激素、胆红素、胆汁酸和胆固醇等内源性化合物的代谢和排泄。以肝脏为基础的代谢性疾病可能是由这些关键途径中的基因突变引起的。已经为这些疾病中的许多创建了转基因或基因敲除小鼠模型,但它们并不总是忠实地复制人类疾病。例如,胆盐输出泵(BSEP)的突变会导致需要整个器官移植的人类患者出现严重的胆汁淤积和纤维化,而基因敲除的小鼠几乎没有表型。虽然许多α-1-抗胰蛋白酶(A1AT)缺乏的患者多次发展为肝纤维化/肝硬变,导致肝移植,但携带突变人类基因的转基因小鼠模型表现出极其温和的表型。鸟氨酸转氨酶(OTC)活性缺乏的小鼠模型是一个公平的模型,但动物可以耐受含有正常蛋白质的饮食,而严重受影响的人类患者需要严格的蛋白质限制以防止致命的高氨血症。小鼠(和大鼠)是研究肝纤维化和肝硬变的特别差的模型,这是许多人类肝病的共同特征。人源化小鼠可能为肝纤维化和肝硬变的研究和治疗提供平台。这些只是不能忠实地再现人类疾病的几个小鼠模型的例子。我们提出的假设是,人类代谢性肝病的最佳模型是那些由受影响的人类肝细胞创建的模型。因此,我们建议通过移植受影响的人类肝细胞来“人性化”FRG小鼠的肝脏,以创建真实的人类代谢性疾病模型。这些小鼠是免疫缺陷的,也缺乏酪氨酸分解代谢酶,延胡索乙酸酯水解酶(Fah-/-),如果不治疗,会发展成不可逆转的肝功能衰竭。然而,如果精通FAH的细胞被移植,它们很容易并迅速地用供体细胞重新填充天然肝脏,即使供体细胞是人类起源的(A)。为了建立这些模型,FRG小鼠的肝脏将用来自代谢性疾病患者的肝细胞进行人源化。此外,iPSC技术将被用于对代谢性疾病患者的肝细胞进行重新编程,在肝脏分化之后,更多的小鼠将被iPS来源的肝细胞人源化。这些人源化的小鼠模型可以在临床化学变化(患者或动物的)、肝脏的组织病理学以及肝组织的基因和蛋白质表达谱方面与真正的疾病肝脏进行比较。通过这种方式,我们将能够确定用这些程序开发的人性化模型是否真实地再现了在患者身上观察到的表型。除了对代谢性肝病的直接影响外,这些模型的成功还将有助于使用人源化的小鼠模型来研究其他基于肝脏的疾病,如肝豆状核变性和阿尔法-1抗胰蛋白酶缺乏症,甚至可能导致更好的人源化模型,用于治疗原发、急性肝功能衰竭和病毒性、酒精性和自身免疫性肝炎,甚至疟疾的肝期,特别是如果在肝脏之外重建人类免疫系统的话。 公共卫生相关性:肝功能的遗传缺陷影响大约1/50,000个活产儿。对于大多数人来说,没有一个小动物模型可以忠实地复制人类的表型。我们提出的假设是,对于这些基于肝脏的疾病,最合适的模型是用真实的受疾病影响的肝细胞产生的模型。最近,我们成功地用人类肝细胞重新填充了专门的小鼠的肝脏。我们建议通过移植代谢性肝病患者的肝细胞来建立人类肝病模型,并表征该模型与人类疾病的相关性。此外,我们将对肝细胞进行重新编程,以产生诱导多能细胞(IPSC),这些细胞也可以用来重新填充和人源化小鼠的肝脏。我们认为这些人源化的小鼠将成为更好地了解人类疾病的技术平台,它将有助于开发基因或细胞疗法来纠正这些毁灭性的疾病。
英文摘要
DESCRIPTION (provided by applicant): Specific Challenge Topic 14-DK-101, "Induced Pluripotent stem cells-cellular and humanized mouse" Somatic cells such as fibroblasts from patients with diseases can be used to create cell lines, tissues, and perhaps, organ systems, through induced pluripotent stem cell (iPSC) technology. Such models could be used to elucidate underlying pathology of disease or screen for agents that could be used therapeutically. Combining this approach with mouse strains able to accept multiple human tissues without rejection could provide the microenvironment milieu to support the tissue's physiological function within the context of the whole organism, enabling greater understanding of disease pathogenesis and providing a platform for preclinical testing of drug candidates." The liver performs over 3,000 functions critical to maintaining the organism, ranging from production and secretion of proteins such as albumin, clotting factors and antiproteases, to metabolism and excretion of exogenous compounds such as drugs or toxins as well as endogenous compounds like hormones, bilirubin and bile acids and cholesterol. Liver-based metabolic disease can result from mutations in genes in these critical pathways. Transgenic or knock-out mouse models have been created for many of these diseases, but they do not always faithfully reproduce the human disease. For example mutations in the bile salt export pump (BSEP) results in severe cholestasis and fibrosis in human patients requiring whole organ transplants, yet the knockout mouse is nearly without a phenotype. While many patients with alpha-1-antitrypsin (A1AT) deficiency develop liver fibrosis/cirrhosis many times resulting in liver transplantation, the transgenic mouse model carrying mutant human genes shows an extremely mild phenotype. The mouse model for a deficiency of ornithine transcarbamylase (OTC) activity, the rate limiting step in ammonia metabolism, is a fair model, however the animals tolerate a diet containing normal amounts of protein, while severely affected human patients require severe protein restriction to prevent lethal hyperammonemia. Mice (and rats) are particularly poor models for studying liver fibrosis and cirrhosis, common features of many human liver diseases. Humanized mice may offer a platform to both the study and treatment of hepatic fibrosis and cirrhosis. These are only a few examples of mouse models that do not faithfully recreate the human disease. We propose, the hypothesis, that the best models for human metabolic liver disease are those created from the affected human hepatocytes. Thus, we propose to" humanize" the liver of FRG mice by transplantation of affected human hepatocytes to create authentic models of human metabolic disease. These mice are immunodeficient and also deficient in the tyrosine catabolic enzyme, fumarylacetoacetate hydrolase (Fah -/-) and develop irreversible liver failure if left untreated. However, if Fah-proficient cells are transplanted, they readily and rapidly repopulate the native liver with donor cells, even if the donor cells are of human origin (a). To create these models, the liver of FRG mice will be "humanized" with hepatocytes derived from patients with metabolic disease. In addition, iPSC technology will be utilized to reprogram the liver cells from metabolic disease patients and following hepatic differentiation, additional mice will be humanized with iPS-derived hepatocytes. These humanized mouse models can then be compared to the authentic diseased liver with respect to changes in clinical chemistry (of the patient or animal), the histopathology of the liver and gene and protein expression profiling of liver tissue. In this manner, we will be able to determine if the humanized models developed with these procedures faithfully reproduce the phenotype observed in the patient. In addition to the direct effects on metabolic liver disease, success with these models will facilitate the use of humanized mouse models to investigate other liver based diseases such as Wilson's and Alpha-1-antitrypsin deficiency and may even lead to better-humanized models for primary, acute liver failure and viral, alcoholic and autoimmune hepatitis and even the hepatic stage of malaria, especially if a human immune system were reconstituted in addition to the liver. PUBLIC HEALTH RELEVANCE: Genetic defects in liver functions affect approximately 1/50,000 live births. For most, there are no small animal models that faithfully reproduce the human phenotype. We propose the hypothesis that the most appropriate model for these liver based diseases is one that is produced with authentic disease-affected hepatocytes. We have recently succeeded in humanizing the liver of specialized mice by repopulating the liver with human hepatocytes. We propose to develop models of human liver disease by transplantation of liver cells from patients with metabolic liver diseases and characterize the model for relevance to the human disease. In addition we will reprogram the liver cells to produce induced pluripotent cells (iPSC) that can also be used to repopulate and humanize the mouse liver. We propose these humanized mice will be a technology platform to better understand the human disease and it will aid in the development of gene or cellular therapy to correct these devastating diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mice Humanized with Hepatocytes and iPS Cells from Patients with Metabolic Diseas
Liver Tissue Cell Line
  • 批准号:
    7139167
  • 项目类别:
  • 资助金额:
    $19.67万
  • 财政年份:
    2005
  • 负责人:
    Stephen C Strom
  • 依托单位:
TOXICITY OF CHEMICALS ASSOCIATED WITH LIPOPROTEINS
  • 批准号:
    3447650
  • 项目类别:
  • 资助金额:
    $5.25万
  • 财政年份:
    1984
  • 负责人:
    Stephen C Strom
  • 依托单位:
TOXICITY OF CHEMICALS ASSOCIATED WITH LIPOPROTEINS
  • 批准号:
    3447649
  • 项目类别:
  • 资助金额:
    $5.2万
  • 财政年份:
    1984
  • 负责人:
    Stephen C Strom
  • 依托单位:
海外基金